
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+5
Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes. Read more: http://www.oramed.com/investors/corporate-presentation Watch: https://www.youtube.com/watch?v=5qChxTDV9eg Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions
Oral insulin,pharmaceuticals,glp-1,diabetes,diabetes type 1,diabetes type 2,insulin,insulin research,diabetes research,and biotech
Oramed pharmaceuticals inc operates in the Pharmaceutical manufacturing industry.
Oramed pharmaceuticals inc's revenue is 11m - 100m
Oramed pharmaceuticals inc has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.